Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ankur V. Dnyanmote is active.

Publication


Featured researches published by Ankur V. Dnyanmote.


Drug Metabolism Letters | 2008

Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats

José E. Manautou; Michael T. Nowicki; Lauren M. Aleksunes; Sharmilee P. Sawant; Ankur V. Dnyanmote; Harihara M. Mehendale

Membrane transporters are critical for the uptake as well as elimination of chemicals and by-products of metabolism from the liver and kidneys. Since these proteins are important determinants of chemical disposition, changes in their expression in different disease states can modulate drug pharmacokinetics. The present study investigated alterations in the renal and hepatic expression of organic anion and cation transporters (Oats/Octs), multidrug resistance-associated proteins (Mrps), breast cancer resistance protein (Bcrp), P-glycoprotein (Pgp), and hepatic Na(+)-taurocholate cotransporting polypeptide (Ntcp) in type 2 diabetic rats. For this purpose, type 2 diabetes was induced by feeding male Sprague-Dawley rats a high fat diet followed by a single dose of streptozotocin (45 mg/kg, i.p., in 0.01 M citrate buffer pH 4.3) on day 14. Controls received normal diet and vehicle. Kidney and liver samples were collected on day 24 for generation of crude plasma membrane fractions and Western blot analysis of Oat, Oct, Mrp, Bcrp, Pgp, and Ntcp proteins. With regards to renal uptake transporters, type 2 diabetes increased levels of Oat2 (2.3-fold) and decreased levels of Oct2 to 50% of control kidneys. Conversely, efflux transporters Mrp2, Mrp4, and Bcrp were increased 5.4-fold, 2-fold, and 1.6-fold, respectively in type 2 diabetic kidneys with no change in levels of Mrp1, Mrp5, or Pgp. Studies of hepatic transporters in type 2 diabetic rats reveal that the protein level of Mrp5 was reduced to 4% of control livers with no change in levels of Bcrp, Mrp1, Mrp2, Mrp4, Ntcp, or Pgp. The changes reported in this study may have implications in type 2 diabetic patients.


Journal of Pharmacology and Experimental Therapeutics | 2003

Potentiation of Carbon Tetrachloride Hepatotoxicity and Lethality in Type 2 Diabetic Rats

Sharmilee P. Sawant; Ankur V. Dnyanmote; Kartik Shankar; Pallavi B. Limaye; John R. Latendresse; Harihara M. Mehendale


Journal of Pharmacology and Experimental Therapeutics | 2005

Protective Effect of Type 2 Diabetes on Acetaminophen-induced Hepatotoxicity in Male Swiss Webster Mice

Sharmilee P. Sawant; Ankur V. Dnyanmote; Mayurranjan S. Mitra; Jaya Chilakapati; Alan Warbritton; John R. Latendresse; Harihara M. Mehendale


Toxicology and Applied Pharmacology | 2006

Type 2 diabetic rats are sensitive to thioacetamide hepatotoxicity.

Sharmilee P. Sawant; Ankur V. Dnyanmote; Alan Warbritton; John R. Latendresse; Harihara M. Mehendale


Toxicology and Applied Pharmacology | 2006

Diabetic mice are protected from normally lethal nephrotoxicity of S-1,2-dichlorovinyl-L-cysteine (DCVC): role of nephrogenic tissue repair.

Ankur V. Dnyanmote; Sharmilee P. Sawant; Edward A. Lock; John R. Latendresse; Alan A. Warbritton; Harihara M. Mehendale


Toxicology | 2007

Mechanisms of inhibited liver tissue repair in toxicant challenged type 2 diabetic rats.

Sharmilee P. Sawant; Ankur V. Dnyanmote; Harihara M. Mehendale


Toxicology and Applied Pharmacology | 2006

Calpastatin overexpression prevents progression of S-1,2-dichlorovinyl-l-cysteine (DCVC)-initiated acute renal injury and renal failure (ARF) in diabetes.

Ankur V. Dnyanmote; Sharmilee P. Sawant; Edward A. Lock; John R. Latendresse; Alan A. Warbritton; Harihara M. Mehendale


The FASEB Journal | 2006

Mechanisms of inhibited liver tissue regeneration in type 2 diabetes following hepatotoxicant challenge

Sharmilee P. Sawant; Ankur V. Dnyanmote; Harihara M. Mehendale


Encyclopedia of Toxicology (Second Edition) | 2005

Appendix 1.19: Food and Drug Administration, US

Ankur V. Dnyanmote; Harihara M. Mehendale


Encyclopedia of Toxicology (Second Edition) | 2005

Appendix 1.35: National Institute for Occupational Safety and Health, US*

Ankur V. Dnyanmote; Harihara M. Mehendale

Collaboration


Dive into the Ankur V. Dnyanmote's collaboration.

Top Co-Authors

Avatar

Harihara M. Mehendale

University of Louisiana at Monroe

View shared research outputs
Top Co-Authors

Avatar

Sharmilee P. Sawant

University of Louisiana at Monroe

View shared research outputs
Top Co-Authors

Avatar

John R. Latendresse

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Alan A. Warbritton

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Alan Warbritton

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jaya Chilakapati

University of Louisiana at Monroe

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kartik Shankar

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge